lutetium lu 177 oncofap-23

lutetium lu 177 oncofap-23 is a small molecule radiopharmaceutical designed for targeted radionuclide therapy of solid tumors that express fibroblast activation protein (FAP), which is overexpressed in more than 90% of epithelial cancers. The drug consists of a high-affinity FAP-targeting ligand, an innovative spacer structure, and a DOTAGA chelator for the incorporation of the radioactive isotope lutetium-177. Upon administration, it selectively accumulates in tumor tissue with minimal uptake in healthy organs and delivers ionizing radiation to induce tumor cell death. Preclinical studies have demonstrated potent anti-tumor efficacy as both monotherapy and in combination with immunocytokines such as L19-IL2. The drug is being developed by Philochem (a subsidiary or affiliate of Philogen) and has entered first-in-human clinical trials for FAP-positive solid tumors[1][2][3][4][5].

Other names

TriOncoFAPOncoFAP radioconjugate therapyOncoFAP radioconjugates